Literature DB >> 19815066

Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity.

Alexandra Kollara1, Theodore J Brown.   

Abstract

Aryl hydrocarbon receptor (AhR) ligands modulate androgen receptor (AR) signaling in prostate cancer cells through partially defined mechanisms. Furthermore, these facilitatory and inhibitory effects of AhR on AR signaling appear to be cell or context specific. In the present study we demonstrate that both AhR and AhR-nuclear translocator (ARNT) interact with AR. AhR but not ARNT enhanced the AR-transcriptional activity which was independent of exogenous AhR ligand treatment (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD). We then tested if coactivators common to both receptors alter the facilitatory effect of AhR on AR activity. NcoA4 overexpression did not alter the AhR facilitatory effect on AR, whereas SRC1 overexpression further enhanced the effect. In contrast, FHL2 overexpression blocked the facilitatory effect of AhR. In the presence of exogenous FHL2 expression, AhR repressed AR activity, whereas at low endogenous levels of FHL2 expression, AhR overexpression enhanced AR activity. At high FHL2 expression levels, TCDD treatment decreased AR activity and this effect was reversed by AhR overexpression. These findings demonstrate that AhR modulation of AR activity is differentially altered by the level of FHL2 and AhR present in the cell. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19815066     DOI: 10.1016/j.jsbmb.2009.09.017

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  15 in total

Review 1.  Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia.

Authors:  Vatsal Mehta; Chad M Vezina
Journal:  Differentiation       Date:  2011 Nov-Dec       Impact factor: 3.880

Review 2.  The FHL2 regulation in the transcriptional circuitry of human cancers.

Authors:  Cyanne Ye Cao; Simon Wing-Fai Mok; Vincent Wing-Sang Cheng; Stephen Kwok-Wing Tsui
Journal:  Gene       Date:  2015-07-26       Impact factor: 3.688

3.  Testosterone-dependent interaction between androgen receptor and aryl hydrocarbon receptor induces liver receptor homolog 1 expression in rat granulosa cells.

Authors:  Yanguang Wu; Sarah C Baumgarten; Ping Zhou; Carlos Stocco
Journal:  Mol Cell Biol       Date:  2013-05-20       Impact factor: 4.272

4.  Involvement of Aryl Hydrocarbon Receptor in L-Kynurenine-Mediated Parathyroid Hormone-Related Peptide Expression.

Authors:  Zhiqing Duan; Jiangong Lu
Journal:  Horm Cancer       Date:  2019-01-28       Impact factor: 3.869

Review 5.  EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals.

Authors:  A C Gore; V A Chappell; S E Fenton; J A Flaws; A Nadal; G S Prins; J Toppari; R T Zoeller
Journal:  Endocr Rev       Date:  2015-11-06       Impact factor: 19.871

Review 6.  Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers.

Authors:  Tatsuo Kanda; Xia Jiang; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

7.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

8.  The aryl hydrocarbon receptor is constitutively active in advanced prostate cancer cells.

Authors:  Oliver Richmond; Maryam Ghotbaddini; Cidney Allen; Alice Walker; Shokouh Zahir; Joann B Powell
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

Review 9.  Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity.

Authors:  Alexandra Kollara; Theodore J Brown
Journal:  Cell Mol Life Sci       Date:  2012-05-05       Impact factor: 9.261

10.  Association between polymorphisms in the aryl hydrocarbon receptor repressor gene and disseminated testicular germ cell cancer.

Authors:  Leon J S Brokken; Yvonne Lundberg-Giwercman; Ewa Rajpert-De Meyts; Jakob Eberhard; Olof Ståhl; Gabriella Cohn-Cedermark; Gedske Daugaard; Stefan Arver; Aleksander Giwercman
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-14       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.